Last reviewed · How we verify
Subtenon Injection of Autologous Platelet-Rich Plasma
Subtenon Injection of Autologous Platelet-Rich Plasma is a Biologic drug developed by Rubens Camargo Siqueira. It is currently in Phase 1 development. Also known as: PRP.
Subtenon injection of autologous platelet-rich plasma (PRP) is an investigational therapy being developed by Rubens Camargo Siqueira for the treatment of retinal diseases, including inherited and degenerative conditions. Early clinical trials have shown promise in improving visual functions, particularly in retinitis pigmentosa and geographic atrophy. The therapy leverages the growth factors and cytokines present in PRP to promote tissue repair and regeneration.
At a glance
| Generic name | Subtenon Injection of Autologous Platelet-Rich Plasma |
|---|---|
| Also known as | PRP |
| Sponsor | Rubens Camargo Siqueira |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Subtenon Injection of Autologous Platelet-Rich Plasma CI brief — competitive landscape report
- Subtenon Injection of Autologous Platelet-Rich Plasma updates RSS · CI watch RSS
- Rubens Camargo Siqueira portfolio CI
Frequently asked questions about Subtenon Injection of Autologous Platelet-Rich Plasma
What is Subtenon Injection of Autologous Platelet-Rich Plasma?
Who makes Subtenon Injection of Autologous Platelet-Rich Plasma?
Is Subtenon Injection of Autologous Platelet-Rich Plasma also known as anything else?
What development phase is Subtenon Injection of Autologous Platelet-Rich Plasma in?
Related
- Manufacturer: Rubens Camargo Siqueira — full pipeline
- Also known as: PRP